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Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide.
Nuclear myocardial perfusion imaging with either single-photon emission computed tomog-
raphy or positron emission tomography has been used extensively to perform diagnosis,
monitor therapies, and predict cardiovascular events. Several radiopharmaceutical tracers
have recently been developed to evaluate CVD by targeting myocardial perfusion, metabolism,
innervation, and inflammation. This article reviews old and newer used in nuclear cardiac
imaging. (J Nucl Cardiol 2018;25:1204–36.)
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Abbreviations
11C-CGP12177 (S)-4-(3-((1,1-dimethylethyl)a-
mino)-2-hydroxypropoxy)-[car-
bonyl-11C]1,3-dihydro-2H-ben-
zimidazol-2-one
11C-CGP12388 (S)-4-(3-(2’-[methine-11C]iso-
propylamino)-2-hydrox-
ypropoxy)-2H-benzimidazol-2-
one
11C-HED [11C]hydroxyephedrine
11C-PK11195 1-(2-chlorophenyl)-N-
[11C]methyl-N-1(1-methyl-
propyl)-3-
isoquinolinecarboxamide
123I-BMIPP b-methyl-p-
[123I]iodophenylpentadecanoic
acid
123I-IPPA p-/o-[123I]iodophenylpentade-
canoic acid
123I-MIBG m-[123I]iodobenzylguanidine
13N-NH3 [
13N]ammonia
15O-H2O [
15O]water
18F-FDG 2-[18F]fluorodeoxyglucose
18F-FEDAC N-benzyl-N-methyl-2-[7,8-dihy-
dro-7-(2-[18F]fluoroethyl)-8-
oxo-2-phenyl-9H-purin-9-
yl]acetamide
18F-FLT [18F]fluorothymidine
18F-FMISO [18F]fluoromisonidazole
18F-FTHA [18F]fluoro-6-thia-heptade-
canoic acid
18F-NaF Sodium [18F]fluoride
68Ga-DOTANOC 68Ga-complex with 1,4,7,10-te-
traazacyclododecane-1,4,7,10-
tetraacetic acid-1-Nal3-
octreotide
68Ga-DOTATATE 68Ga-complex with 1,4,7,10-te-
traazacyclododecane-1,4,7,10-
tetraacetic acid-D-Phe1-Tyr3-
octreotate
68Ga-DOTATOC 68Ga-complex with 1,4,7,10-te-
traazacyclododecane-1,4,7,10-
tetraacetic acid-D-Phe1-Tyr3-
octreotide
99mTc-MIBI 99mTc-sestamibi
acetyl-CoA Acetyl coenzyme A
Ach Acetylcholine
ATP Adenosine triphosphate
CVD Cardiovascular disease
CMR Cardiac magnetic resonance
COMT Catechol-O-methyltransferase
ECG Electrocardiographically
FDA Food and Drug Administration
FFA Free fatty acid
HFpEF Heart failure with preserved
ejection fraction
HF Heart failure
HMR Heart-to-mediastinum ratio
HR Heart rate
ICD Indication for cardioverter-de-
fibrillator implantation
LMI1195 N-(3-bromo-4-(3-[18F]fluoro-
propoxy)benzyl)-guanidine
LV Left ventricular
MAO Monoamine oxidase
MBF Myocardial blood flow
MPI Myocardial perfusion imaging
NE Norepinephrine
PAP Pulmonary artery pressure
PET Positron emission tomography
PH Pulmonary hypertension
PS Phosphatidylserine
RV Right ventricle
SPECT Single-photon emission com-
puted tomography
TCA Tricarboxylic acid
TSPO Translocator protein 18kDa
VMAT Vesicular monoamine
transporter
WBC White blood cell
b-AR b-adrenergic receptor
INTRODUCTION
Cardiovascular disease (CVD) is the leading cause
of death and disease burden around the world.1
Advances in single-photon emission computed tomog-
raphy (SPECT) and positron emission tomography
(PET), which allow for non-invasive imaging, are
vastly improving the evaluation of myocardial perfu-
sion and function.2,3 Nuclear cardiac imaging is useful
to perform diagnosis and risk assessment and to
monitor the impact of therapies through serial imaging.
Several radiopharmaceutical tracers are used in nuclear
cardiology imaging to target perfusion, metabolism,
innervation, and inflammatory conditions. Nuclear
imaging tests are suitable for almost all patients given
the low possibilities of side effects from radiopharma-
ceutical tracers other than minimal radiation exposure.
In this article, we will review SPECT and PET tracers
used in assessing CVD.
See related editorial, pp. 1242–1246
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TRACERS USED FOR CARDIAC IMAGING
(TABLE 1)
Inorganic Tracers
Inorganic compounds 13N-ammonia (13N-NH3) and
15O-water (15O-H2O) have been used for cardiac perfu-
sion imaging.4 Both tracers are labeled with short-lived
positron emitters (13N: 10 minute; 15O: 2 minute), which
are therefore produced with an onsite cyclotron. 15O-
H2O is freely diffused into cardiomyocytes. In contrast,
the uptake mechanism of 13N-NH3 is unclear.
5 Almost
all ammonia molecules in the blood would be protonated
to form NH4
? because of its pKa (9.3 at 25 C). The
ammonium cation would barely penetrate cell mem-
branes to enter cardiomyocytes.
Radiometal Ions
In addition to these inorganic compounds, several
radiometal ions have been used as cardiac imaging
tracers, especially in myocardial perfusion imaging.
Initially, the monovalent cation of potassium-43 (43K?),
a c-emitter, was used for imaging of myocardial perfu-
sion.6 However, the main gamma energy of this
radionuclide (0.37 and 0.67 MeV) is somewhat too high
for SPECT imaging. Also 43K has a relatively long half-
life (22 hours) and emits relatively high-energy b-
particles [300 keV (mean)]. K? is actively transported
into the myocyte by the cell membrane via Na?/K?
pumps. Therefore, other monovalent cations that emit c-
rays suitable for SPECT imaging were sought. The ionic
radius of the candidate should be comparable to that of
K? (138 pm) to be a substrate of a Na?/K? pump. The
monovalent cation of thallium-201 (201Tl?, ionic radius;
150 pm) fulfills these requirements and has been widely
used for diagnosis of coronary artery disease (CAD).
Although 201Tl emits c-rays of 135 and 167 keV,
abundantly emitted characteristic x-rays (69 to 80 keV)
are used for imaging.
A positron emitter, rubidium-82 (82Rb), has an ionic
radius (152 pm) comparable to that of K? in its
monovalent cationic form (82Rb?) and belongs to the
Table 1. Classification of cardiac imaging tracers by characteristics
Characteristics Tracer
Inorganic tracers 13N-NH3
15O-H2O
Radiometal ions 201Tl?
82Rb?
67Ga3?
18F-
Small organic tracers 11C-acetic acid
11C-palmitic acid
123I-IPPA
18F-FDG
123I-BMIPP
18F-FTHA
11C-epinephrine
18F-fluorodopamine
Derivatives of guanethidine, metaraminol, and vesamicol
Neuroreceptor ligands such as prazosin (a-blocker), carazolol
(b-blocker) derivative, b-agonists (CGP12177 and CGP12388),
and quinuclidinyl benzilate (anticholinergic compound)
11C-PK11195
18F-FEDAC
Radiometal complex tracers 99mTc-sestamibi
99mTc-tetrofosmin
Somatostatin analogs and annexin V tagged with 64Cu, 68Ga, or 99mTc
99mTc-tagged annexin A5
111In-oxine
99mTc-HMPAO
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same family as K (alkaline metals). The kinetics of Rb?
are similar to those of K?7, and therefore, 82Rb? has
been widely used as a perfusion imaging tracer with
PET in the United States (USA).8 In addition, the use of
a positron-emitting isotope of K, potassium-38, has been
also reported.9 Trivalent cations of gallium-67 (67Ga3?),
a c-emitter, have been used to detect inflammatory
lesions. Ga3? binds to ferric iron (Fe3?)-binding pro-
teins such as transferrin and lactoferrin which are
accumulated in inflammatory lesions.10 Besides cationic
radionuclides, a monovalent anion of fluorine-18 (18F-)
that is used for bone imaging has been used for imaging
calcification lesions with PET.11
Small Organic Tracers
Tracers of radiolabeled small organic compounds
are used for imaging metabolism, synaptic function, and
inflammation. In metabolic imaging, radiolabeled bio-
molecules and their derivatives are used. Biomolecules,
acetic acid, and palmitic acid, substrates of oxygen
metabolism and fatty acid metabolism, have been
labeled with carbon-11 (11C-acetic acid and 11C-palmi-
tic acid) and used for the assessment of respective
myocardial metabolism.12 Iodophenylpentadecanoic
acid labeled with iodine-123, (123I-IPPA) is also a
substrate of fatty acid metabolism. For labeling with
123I, a phenyl group was incorporated into the structure
of palmitic acid. In the development of tracers, deriva-
tization of a biomolecule is often performed to obtain a
compound that is metabolized by a certain metabolic
step without undergoing further metabolism. 2-[18F]flu-
orodeoxyglucose (18F-FDG) is one such derivative of
glucose. b-methyl-p-[123I]iodophenylpentadecanoic acid
(123I-BMIPP) and [18F]fluoro-6-thia-heptadecanoic acid
(18F-FTHA) introduce a methyl group and thioether in
the alkyl chain, respectively, to terminate b-oxidation in
the course of fatty acid metabolism.
In presynaptic cardiac imaging, a radiolabeled
catecholamine and its derivative are also used as a
tracer. 11C-labeled epinephrine and 18F-labeled fluo-
rodopamine (18F-fluorodopamine) have been used to
image the presynaptic sympathetic nervous system.13 In
addition to biomolecules, xenobiotics including thera-
peutics are radiolabeled and used as tracers. Derivatives
of guanethidine, metaraminol, and vesamicol are used
for presynaptic imaging, and neuroreceptor ligands such
as prazosin (a-blocker), carazolol (b-blocker) derivative,
b-agonists CGP12177 and CGP12388, and quinuclidinyl
benzilate (anticholinergic compound) derivatives are
used for neuroreceptor imaging (Table 4).13
Radiolabeled receptor ligands for translocator pro-
tein 18 kDa (TSPO), peripheral-type benzodiazepine
receptors, have also been used to image inflammation.
TSPO is highly expressed in activated cells of the
mononuclear phagocyte.14
Radiometal Complex Tracers
Some tracers used in nuclear cardiology are radio-
metal complexes containing copper-64 (64Cu), gallium-
68 (68Ga), or technetium-99m (99mTc). They are clas-
sified into two groups. One contains those complexes
that are used as tracers on their own. 99mTc is used to
form a complex with six methoxyisobutylisonitrile
(99mTc-sestamibi) and two 1,2-bis(di(2-
ethoxyethyl)phosphino) ethane (99mTc-tetrofosmin),
which have been used for myocardial perfusion imaging.
Their bulky structures contribute to reducing protein
binding in the blood through steric hindrance. These
tracers are positively charged (monovalent) but lipophi-
lic. Therefore, they can be diffused into myocytes.
The other group includes complexes used as tags for
peptides and proteins. Somatostatin analogs and annexin
V tagged with 64Cu, 68Ga, or 99mTc have been used for
imaging symptomatic carotid atherosclerosis.15 64Cu or
68Ga-tagged somatostatin analogs bind to somatostatin
receptor subtype-2, which is upregulated in macro-
phages. 99mTc-tagged annexin A5 binds to
phosphatidylserine, which is externalized in apoptotic
cells.
White blood cells enclosing radiometals, which are
used for imaging infectious lesions, are prepared using
lipophilic radiometal complexes. Indium-111 (111In)
complexed with 8-hydroxyquinolines (111In-oxine) and
99mTc complexed with exametazime (99mTc-HMPAO)
are diffused into the leucocyte. The subsequent disso-
ciation of ligands results in enclosure of these
radiometals in the cell.
RADIOTRACERS CATEGORIZED BY USE
Perfusion Imaging
Myocardial blood flow (MBF) is supplied by
coronary arteries to preserve adequate myocardial oxy-
gen supply. At rest, coronary artery stenosis must exceed
85% to 90% of luminal diameter before there is a
significant decrease of MBF. In contrast, maximal
coronary flow has been shown to be reduced with
stenosis of 45% to 50% under stress condition.16
Myocardial perfusion images during stress and rest are
compared to detect the stress-induced ischemic change
or myocardial injury (Figure 1).17,18 Several perfusion
tracers are used to assess coronary artery disease (CAD)
(Table 2, Figure 2).17,19–22
SPECT tracers for perfusion imaging. Thal-
lium-201 (201Tl), technetium-99m (99mTc)-sestamibi,
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and 99mTc-tetrofosmin are available for SPECT myocar-
dial perfusion imaging (MPI).
99mTc-labeled myocardial perfusion tracers.
Thallium-201
201Tl, introduced in the 1970 s, was the first SPECT
MPI tracer available in a clinical setting.23 In 1975,
Wackers et al. reported on the imaging of acute
myocardial infarction with 201Tl.24 201Tl is produced in
a cyclotron and has a relatively long half-life (73 hours),
and therefore requires lower injection doses to minimize
radiation exposure. 201Tl is a potassium analog and is
transported into the myocyte via cell membrane Na?/K?
pumps during the first transit in proportion to regional
MBF.
201Tl emits low-energy photons (71 to 80 keV),
therefore requiring longer imaging acquisition times and
resulting in limited image quality due to absorption and
photon scattering especially in obese patients. Biodis-
tribution of 201Tl is generally proportional to organ
blood flow. Injected 201Tl is rapidly cleared from the
blood with maximal concentration by normal myocar-
dium (5% to 8% remains in the blood at 5 minutes). The
whole-body retention curve can be represented by a
biexponential curve. 201Tl is excreted slowly in both
feces and urine. Approximately 4% to 8% of the
administered dose is excreted in the urine in the first
24 hours.25,26 Lung uptake of 201Tl is generally low. An
increased lung uptake is known to be associated with
greater segmental myocardial perfusion abnormality,
increased severity and extent of CAD, and subsequent
adverse cardiac events.27
Whole-body radiation exposure after an injection (2
to 4 mCi) is up to * 25 mSv.28,29
201Tl has a higher extraction coefficient than do
99mTc-labeled perfusion tracers (Figure 3). The higher
extraction fraction may be an advantage for MBF
quantification.30
Stress images are acquired 5 to 15 minutes after
tracer injection in order to avoid the ‘‘upward creep’’
phenomenon due to rapid respiration if the stress is
produced through exercise. Redistribution images are
acquired 2 to 4 hours after initial injection. Differential
washout rates of normal regions (with faster washout) vs
regions with ischemic segments (slower washout) con-
tribute to the redistribution or normalization of the
abnormal regions in delayed images.
99mTc-labeled myocardial perfusion trac-
ers. 99mTc is a generator-produced agent eluted from
molybdenum-99 (99Mo). Despite its initial Food and
Drug Administration (FDA) approval, 99mTc-teborox-
ime is far less commonly used due to the excessive
initial uptake in the myocardium and rapid washout.31,32
99mTc-sestamibi and 99mTc-tetrofosmin have had wide-
spread clinical use. The first use of 99mTc-tetrofosmin
for humans was reported in 1993 as part of a phase 1
clinical trial.33 Injected 99mTc-labeled perfusion tracer
distributes in the myocardium according to regional
myocardial perfusion. Its uptake by myocardium is
related to the presence of intact mitochondria.34
Because its half-life is 6 hours, the administered
dose is relatively larger and the radiation exposure is
lower respectively than those associated with 201Tl.29
The peak energy level of c-rays from 99mTc is about 140
keV, which is suitable for c-camera imaging and
electrocardiographically (ECG) gated myocardial perfu-
sion SPECT.
99mTc-sestamibi is rapidly cleared from blood after
intravenous administration. Lung uptake is generally
Figure 1. Myocardial perfusion images Perfusion images of short-axis image at stress (A) and
rest (B), vertical long-axis image at stress (C) and rest (D) using 99mTc-product, and fused image
of stress perfusion and CT coronary angiography (CTCA; E) are displayed. Severe perfusion
reduction is detected in the inferior wall at stress (white arrows). Fill-in is seen at rest indicating
stress-induced ischemia in the right coronary artery (RCA). CTCA revealed significant stenosis
in the RCA (orange arrows).
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low. However, marked accumulation is present in liver
and spleen at resting condition during the first 60
minutes after injection. After an injection with exer-
cise stress, substantially less uptake is observed in the
liver and spleen with excellent visualization of heart.35
99mTc-tetrofosmin is rapidly cleared from the blood (\
5% remains in blood by 10 minutes) after intravenous
administration. Uptake in myocardium is approxi-
mately 1.2% with minimal redistribution, and
approximately 1% at 2 hours. Clearance from liver
is quick (\ 4.5% remains by 60 minutes) and lung
uptake is also rapidly reduced.33,36,37 Myocardial
uptake of 99mTc-tetrofosmin is higher from 5 to 60
minutes than is that for 99mTc-sestamibi. The biolog-
ical half-life of 99mTc-tetrofosmin in normal
myocardium and liver is significantly shorter than
that of 99mTc-sestamibi. Heart-to-lung ratios for
99mTc-tetrofosmin and 99mTc-sestamibi are similar,
whereas heart-to-liver ratios for 99mTc-tetrofosmin
are significantly higher from 30 to 60 minutes post
injection compared to those for 99mTc-sestamibi.37,38
Total whole-body radiation after a typical injection
dose (10 to 25 mCi) is * 10.6 mSv for 99mTc-
tetrofosmin and 12.0 mSv for 99mTc-sestamibi.28
Separate stress and rest injections are required for
the detection of stress-induced ischemia due to its slow
clearance from myocytes. Both 99mTc-sestamibi and
99mTc-tetrofosmin have lower extraction coefficients
than does 201Tl (Figure 3).39 Recent SPECT systems
allow the quantification of MBF from dynamic tracer
imaging due to the improved sensitivity and temporal
resolution.40,41
PET tracers for myocardial perfusion
imaging. Several PET tracers can be used to assess
myocardial perfusion.18 These include 82Rb, 13N-NH3,
and 15O-H2O (Figure 4).
19 Both 13N-NH3 and
82Rb are
commonly used for both qualitative and quantitative
measurements.34,42–44 Visual assessment of PET
myocardial perfusion imaging provides high diagnostic
accuracy in the detection of CAD.17 Dynamic imaging
analysis permits quantitative assessment of MBF and
coronary flow reserve (CFR), which is defined as the
Figure 2. Schematic representation of tracers for assessing myocardial perfusion 201Tl and 82Rb
are potassium analogs and are transported into the myocyte by cell membrane Na?/K? pumps.
Injected uptake of 99mTc-sestamibi, 99mTc-tetrofosmin, and 18F-flurpiridaz in the myocardium is
related to the presence of intact mitochondria. The uptake mechanism of 13N-NH3 is unclear.
After being taken into the myocyte, 13N-NH3 underwent metabolic trapping with the conversion
of NH3 to glutamine, glutamic acid, and carbamoyl phosphate.
15O-H2O is metabolically inert
and freely diffusible tracer.
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ratio of MBF at peak hyperemia to MBF at rest. CFR
measurements provide additional value in the detection
of multi-vessel disease and risk stratification of CAD
patients.45–49 15O-H2O is an ideal myocardial flow tracer
to quantify MBF with a linear relation between first-pass
extraction and perfusion, but the perfusion images are
not of high quality as they are with the other 2 PET
tracers (Figure 3).19,30,50,51
82Rb is the most widely used tracer because it is a
strontium-82 (82Sr)/82Rb generator-produced tracer that
does not require a cyclotron for its production.52,53 Love
et al. initially developed rubidium-86 for myocardial
perfusion imaging with a dog.7 Following non-human
studies, Selwyn et al. applied 82Rb to a human for the
first time in 1982.54. The short physical half-life of 82Rb
(76 seconds) enables sequential rest/stress scanning.
82Rb is a potassium analog, and therefore injected 82Rb
is actively transported into myocytes through the Na?/
K? adenosine triphosphate (ATP) transport system. This
uptake of 82Rb is dependent on MBF and its first-pass
retention fraction is approximately 65% at rest. The
relatively low lesion contrast with low spatial resolution
due to the lower extraction fraction and high positron
range is a slight disadvantage of 82Rb.39 In 2000, 13N-
NH3 PET was approved by the United States Food and
Drug Administration (FDA) to evaluate myocardial
perfusion in patients with known or suspected CAD.19
13N-NH3 was also approved by the Japanese Ministry of
Health and Welfare in March 2012 (Table 2).55
The uptake mechanism of 13N-NH3 is unclear. After
being taken into the myocyte, 13N-NH3 underwent
metabolic trapping with the conversion of NH3 to
glutamine, glutamic acid, and carbamoyl phosphate.56
13N-NH3 PET is suitable for imaging and measuring of
MBF due to its high first-pass extraction fraction and
retention in the myocardium with rapid clearance from
the blood pool, which also give it high diagnostic
accuracy.57 The requirement for a cyclotron limits the
clinical use of 13N-NH3. Its relatively longer half-life
(9.96 minutes) necessitates a longer interval between
rest and stress scans, resulting in low throughput in a
clinical setting. These are the main disadvantages of
13N-NH3.
39 The FDA has approved 82Rb and 13N-NH3
for clinical use (Table 2). The Japanese Ministry of
Health, Labour, and Welfare has approved 13N-NH3 for
detecting CAD in cases of CAD unable to be diagnosed
with using SPECT MPI.55
15O-H2O is unique in being metabolically inert and
freely diffusible, which are considered ideals for mea-
suring MBF due to the linear relationship between first-
pass extraction and perfusion.58 The shorter half-life
(2.04 minutes) enables consecutive rest/stress protocols,
similar to the case with 82Rb.59,60 However, 15O-H2O
requires an on-site cyclotron for tracer production and
also is suboptimal for visual assessment due to the low
signal-to-noise ratios. These conditions lead to its use
being limited in clinical settings. 15O-H2O has gained
wide popularity in research settings due to its excellent
kinetic properties.19,61–63 A recent study by Danad et al.
examined stress MBF and CFR in 330 patients with
CAD,64 possibly indicating that 15O-H2O could move
from research to clinical use.
Fluorine-18 (18F)-flurpiridaz, an analog of the
insecticide pyridaben, is a novel MPI tracer that can
bind to the mitochondrial complex-1 inhibitor.51,65 The
positron range of 18F is 1.03 mm, shorter than that of
other PET perfusion tracers (Table 2). Injected 18F-
flurpiridaz shows very high first-pass extraction and high
affinity in myocardial tissue with slow washout from
cardiomyocytes (Figure 3). Therefore, accurate quan-
tification of MBF and CFR measurements with high
image quality and excellent diagnostic accuracy are
expected.66–68 Because of the longer half-life of 18F
(109.8 minutes), delivery of unit doses from regional
cyclotrons may be possible, similar to the case with
fluorine-18-labeled fluorodeoxyglucose (18F-FDG). In
the meantime, repeated measurements of stress and rest
studies would likely be difficult due to the longer half-
life, and therefore a separate day protocol or some
correction for the residual activity of the first acquisition
might be needed. Phase 2 clinical trials showed
promise,67 and phase 3 clinical trials demonstrated the
diagnostic usefulness for specific subpopulations such as
women and obese patients.
Figure 3. Extraction fraction of each perfusion tracer The
extraction fraction of 15O-H2O is nearly 100% due to its
exclusive property of being metabolically inert and freely
diffusible. The extraction fraction of 82Rb is lower than that of
the other PET tracers. 201Tl has a higher extraction fraction
compared to that associated with 99mTc-MIBI.
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Metabolic Imaging
The heart derives its energy from a variety of
sources such as free fatty acids (FFA), glucose, lactate,
and ketone bodies (Figure 5).69 Glucose metabolism
dominates after feeding, and fatty-acid metabolism
dominates under long-fasting conditions.69 Carbohy-
drates taken into cardiomyocytes are metabolized into
pyruvic acid using various enzymatic actions. If oxygen
supply is sufficient, ATPs are produced from glucose via
the glycolysis system in the tricarboxylic acid (TCA)
cycle and electron transfer system.70 In the ischemic
state, acid metabolism is impaired due to insufficient
oxygen supply to the myocardium.71 Alternatively ATP
is produced from lactic acid because anaerobic glycol-
ysis with less oxygen consumption becomes
predominant. However, anaerobic glycolysis produces
less ATP than does aerobic glycolysis. If severe
myocardial ischemia continues, myocardial cells
become necrotic as ATP production diminishes.72 Sev-
eral SPECT and PET tracers have been used or tried
clinically to assess myocardial metabolism (Table 3,
Figure 6).
SPECT tracers for metabolic imaging. For
fatty acid metabolism evaluation, SPECT examination
using iodine-123-labeled beta-methyl-p-iodophenylpen-
tadecanoic acid (123I-BMIPP) has been clinically used in
Japan.44,73,74 However, 123I-BMIPP was initially devel-
oped in the United States and the first human use was in
1986 by Knapp et al.75 After the initial development in
the US, the Japanese community took over development
of 123I-BMIPP. The first human use in Japan was
reported in 1991 in a Japanese article.76 Following this
Japanese article, Kurata et al. reported Japanese 123I-
BMIPP data in an international journal in 1992.77 123I-
BMIPP is an iodinated fatty-acid analog used to assess
myocardial fatty acid metabolism.78,79 This tracer,
however, is not approved for clinical use in the US
despite its successful for clinical use even successive
early experience use in that country.80 Iodine-123-
labeled iodophenylpentadecanoic acid (123I-IPPA) is a
radiolabeled free fatty acid (FFA) analog which is in
phase 3 trials in United States but which has not yet been
approved.81
Following intravenous injection, 123I-BMIPP and
123I-IPPA are rapidly distributed to various organs, such
as liver and heart, and cleared rapidly from the
blood.81–84 Initial uptake of the administered dose of
123I-BMIPP is assumed to be about 6% by the heart and
14% by the liver. The residual 123I-BMIPP is distributed
uniformly in other organs and tissues.76,85,86 After initial
uptake, only a portion of the 123I-BMIPP and 123I-IPPA
is metabolized immediately to water-soluble low-molec-
ular-weight products. Most of the 123I-IPPA undergoes
metabolism similar to that of long-chain fatty acids,
through rapid mitochondrial beta-oxidation.87,88 The
initial and late clearance of 123I-IPPA are thought to
reflect b-oxidation and clearance of tracer incorporated
into triglyceride pools, respectively.88 123I-IPPA images
show minimal background activity and good image
quality. The metabolism of 123I-BMIPP is slower than
that of 123I-IPPA because 123I-BMIPP is a modified-
branched fatty acid analog with a methyl group on the
beta-carbon. Both of the end products are excreted in a
conjugated form in the urine.76,89,90
123I-BMIPP scintigraphy when combined with per-
fusion imaging may show preserved perfusion, but fatty
acid metabolism is impaired as myocardium shifts from
metabolizing fatty acids to metabolizing predominantly
glucose following ischemic episodes. Therefore, the
region of perfusion-metabolic mismatch (123I-BMIPP
defect larger than perfusion defect) indicates the pres-
ence of ischemic myocardium (Figure 7). 80,91–93 123I-
BMIPP has been approved in Japan only for clinical
use.44
PET tracers for metabolic imaging. 18F-FDG
is the most frequently used tracer around the world and
is employed mainly for the assessment of malignant
tumors. For the purposes of nuclear cardiology imaging,
18F-FDG PET was first used to define and identify viable
myocardium in CAD in the 1980 s.94 Since 18F-FDG is
an analog of glucose, once taken up into the cardiomy-
ocytes via the glucose transporter (GLUT), it is
phosphorylated to 18F-FDG-6-phosphate by hexokinase
as well as glucose.95 18F-FDG-6-phosphate accumulates
intracellularly without being metabolized during glycol-
ysis, a condition referred to as ‘‘metabolic trapping’’
(Figure 6). Therefore, myocardial viability can be
Figure 4. Qualitative images of PET tracers 82Rb PET has relatively low lesion contrast with
low spatial resolution. 13N-NH3 PET shows clear images due to rapid clearance from the blood
pool. With 15O-H2O PET, it is difficult to distinguish between myocardium and blood pool.
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evaluated by assessing the accumulation of 18F-FDG in
myocardium. To determine myocardial viability, oral
glucose loading or an insulin-glucose clamp is applied to
enhance 18F-FDG uptake in viable myocardium.96,97 In
ischemic myocardium, 18F-FDG accumulation in the
myocardium is maintained under a fasting condition due
to the dominant anaerobic glucose metabolism. On the
other hand, in the infarcted scar tissue, 18F-FDG
accumulation is absent due to non-availability of glu-
cose metabolism. In a clinical setting, 18F-FDG PET
viability assessment is performed using the myocardial
perfusion image obtained by SPECT or PET.94,98 A
region with preserved 18F-FDG accumulation but
reduced myocardial perfusion indicates viable myocar-
dium. In such a case, functional recovery after coronary
revascularization is likely especially with extensive
mismatch pattern.
11C-palmitate and fluorine-18-labeled fluoro-6-thia-
heptadecanoic acid (18F-FTHA) have been used to
evaluate fatty acid metabolism.99–101 Similar to the case
with to 18F-FDG PET, a shift in myocardial metabolism
from fatty acid to glucose can be estimated using these
fatty acid analogs.102
Myocardial oxygen metabolism can be non-inva-
sively evaluated by 11C-acetate PET.103,104 11C-acetate
taken into myocardium is converted into acetyl-CoA,
consecutively metabolized and excreted into 11C-CO2
via the TCA cycle. The 11C-acetate clearance rate is
used to assess myocardial oxygen consumption since
TCA cycle activity is directly linked with myocardial
oxygen consumption which is independent of the con-
centration of energy substrates for the
myocardium.105,106 11C-acetate PET allows for non-
invasive observation of regional myocardial oxygen
metabolism in the presence of ischemia,107,108 car-
diomyopathy,109,110 and heart failure (HF) in a state of
deprived energy.111,112 Myocardial oxidative metabo-
lism in the RV can also be estimated using 11C-acetate
PET.113–116 11C-acetate PET permits the evaluation of
both blood flow and oxygen metabolism with one
examination using some model analysis due to the
relatively high extraction fraction.62
Sympathetic Imaging
The heart has extensive innervation, both sympa-
thetic and parasympathetic. The sympathetic nervous
system uses norepinephrine (NE), and the parasympa-
thetic nervous system uses acetylcholine (Ach) as the
main neurotransmitters. NE is synthesized from the
Figure 5. Schematic representation of cardiac energy metabolism Substrates are transported
across the extracellular membrane into the cytosol through GLUT for glucose and FAT for fatty
acid. Metabolized intermediates such as pyruvate and acyl-CoA are transported across the inner
mitochondrial membrane for oxidation. Then inside the mitochondrion, substrates are oxidized
or carboxylated and fed into the TCA cycle and ETC to produce ATP. GLUT, glucose
transporter; FAT, fatty acid transporter; G-6-P, glucose-6-phosphate; ATP, adenosine triphos-
phate; TCA, tricarboxylic acid; ETC, electron transport chain; CA I, carnitine acyltransferase I;
CA II, carnitine acyltransferase II.
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Figure 6. Tracers for assessing cardiac energy metabolism 18F-FDG is a glucose analog in
which the oxygen in position C-2 is replaced with 18F. 18F-FDG is actively transported into the
cell mediated by GLUT in the same way as glucose. Once inside the cell, glucose and 18F-FDG
are phosphorylated by hexokinase. Phosphorylated glucose (G-6-P) continues along the
glycolytic pathway for energy production. However, 18F-FDG-6-phosphate cannot enter
glycolysis and is trapped intracellularly in a condition known as ‘‘metabolic trapping.’’ GLUT,
glucose transporter; G-6-P, glucose-6-phosphate; FDG, 18F-fluorodeoxyglucose; FDG-6-P, 18F-
FDG-6-phosphate.
Figure 7. Ischemic memory imaging Perfusion image of 99mTc product shows slightly reduced
perfusion (A, C), whereas moderately reduced 123I-BMIPP uptake is seen in the anterior to
septal wall (B, D), which indicates perfusion-metabolic mismatch. Coronary angiogram shows
no significant stenosis (E); however, vasospastic angina in the left anterior descending artery due
to the spasm is proved through intracoronary injection of acetylcholine (F).
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amino acid tyrosine in presynaptic neurons (Figure 8).
NE is transported into the presynaptic neuronal terminal
vesicles by the vesicular monoamine transporter
(VMAT). Exocytosis is led by the activation of volt-
age-dependent calcium channels and vesicles at the
presynaptic neuron. Some of the NE released into the
synaptic cleft binds to the adreno-receptors for down-
stream effects, while much of the NE undergoes
reuptake into presynaptic neurons via the terminal
transporter (uptake-1).117–119
The sympathetic nerve is vulnerable to ischemia,
and sympathetic nervous function may decline even if
myocardial blood flow at rest is maintained.120 In HF,
continued stimulation of the b1 receptor due to
increased norepinephrine levels results in a decrease of
receptor density (down regulation), with corresponding
poor reactivity to the stimulation. Moreover, in a
persistent state of sympathetic hyperactivity, the ability
to retain norepinephrine is also decreased at the nerve
terminal end.121 Abnormal neuro-hormonal function is
reported in various heart diseases, and worsening of
neuronal function is associated with cardiac events and
sudden cardiac death.122–124
SPECT tracers for sympathetic imag-
ing. Iodine-123-labeled metaiodobenzylguanidine
(123I-MIBG) is widely used as a SPECT tracer to
evaluate the presynaptic sympathetic innervation of the
heart.125–127 The first use of 123I-MIBG in humans was
in 1981 by a University of Michigan group.128 It is an
analog of catecholamine, which is taken up via the
uptake-1 mechanism and stored in synaptic vesicles as is
NE. Tracers are released into the synaptic cleft from the
synaptic vesicle via the exocytosis pathway, but do not
lead to any physiological activity without binding to the
catecholamine receptor. Since it is not metabolized by
monoamine oxidase (MAO) or catechol-O-methyltrans-
ferase (COMT), most of the released tracer is reabsorbed
at the synapse terminal and again stored in synaptic
vesicles. Therefore, information reflecting the process of
123I-MIBG uptake into the synapse terminal, storage in
the vesicles, secretion, reabsorption, and release into the
blood is obtained from sympathetic imaging.129,130 An
early anterior planar image at 15 minutes after injection
and a late anterior planar image starting at 3 to 4 hours
after injection are acquired to calculate the heart-to-
mediastinum ratio (HMR) and the washout ratio (Fig-
ure 9). These parameters are considered to be standards.
The high liver uptake and relatively high energy of the
tracers make the image quality suboptimal. It is difficult
to evaluate SPECT images especially in severe HF,
which usually has limited myocardial 123I-MIBG
radioactivity. Therefore, planar data acquisition is stan-
dard for 123I-MIBG imaging.131 Although these images
present an easily obtained index, inter-institutional
differences of the HMR due to differences in camera-
collimator systems being used have hampered multi-
center comparisons. Recently, standardization among
different collimator types has been achieved using the
calibration phantom and could easily be extrapolated to
the images of other institutions.132,133 Late HMR pro-
vides the relative distribution of cardiac sympathetic
nerve terminals, which is related to neuronal function
from uptake to release. Washout ratio represents the
information of the sympathetic drive. Several studies
have presented that patients with chronic HF and a low
late HMR and/or an increased washout rate are at
increased risk for cardiac death.
PET tracers for sympathetic imaging. As a
PET tracer, carbon-11-labeled hydroxyephedrine (11C-
HED) is used mainly to assess presynaptic cardiac
sympathetic nerve distribution.134 11C-HED is still the
most widely used PET tracer for sympathetic nervous
function imaging in mainly research settings.135 Extrac-
ardiac uptake is mainly by the liver with very limited
lung uptake. In ischemic heart disease, a mismatch
region of myocardial blood flow and sympathetic
dysfunction is reported as a decision criterion for
prediction of fatal arrhythmia and indication for car-
dioverter-defibrillator implantation (ICD).136,137 The
distribution abnormality of cardiac sympathetic dener-
vation has been demonstrated in previous 11C-HED
studies, including those involving patients with
HF,138,139 cardiac arrhythmias,140,141 myocardial infarc-
tion,142,143 cardiac diabetic neuropathy,144,145 and HF
with preserved ejection fraction (HFpEF).146
N-[3-bromo-4-(3-18F-fluoro-propoxy)-benzyl]-guani-
dine (LMI 1195) is a novel 18F-labeled ligand to image the
norepinephrine transporter.147 18F-fluorometaraminol,148
11C-phenylephrine,149 18F-fluorodopamine,150 and
Figure 8. Schema of myocardial adrenergic neuronal termi-
nals Figure A shows the schematic representation of
myocardial adrenergic neuronal terminals and Figure B shows
the chemical structure of each tracer. MIBG is actively taken
up into sympathetic nerves through the uptake-1 mechanism
and then stored in the synaptic vesicle in a manner similar to
that for norepinephrine (NE). Nerve stimulation releases
MIBG and NE into the synaptic cleft through exocytosis.
MIBG does not bind to the postsynaptic receptor and is not
metabolized by monoamine oxidase (MAO) or catechol-O-
methyltransferase (COMT). Most of the released MIBG
undergoes reuptake through the uptake-1 mechanism, and the
remaining MIBG goes into the blood (spillover). 123I-MIBG,
m-[123I]iodobenzylguanidine; 11C-HED, 11C-hydrox-
yephedrine; DAG, diacylglycerol; AR, adrenergic
receptor;Gq, phospholipase C-coupled Gq-protein; Gs, phos-
pholipase C-coupled Gs-protein; ATP, adenosine triphosphate;
cAMP, cyclic adenosine monophosphate; IP2, inositol bispho-
sphate; PIP2, phosphatidylinositol biphosphate.
b
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11C-epinephrine151 are the other radiotracers for evaluating
presynaptic neuronal function. Several tracers such as 18F-
fluorocarazolol,152 4-[3-[(1,1-dimethyl)amino]-2-hydrox-
ypropoxy]-1,3-dihydro-2H-benzimidazol-2-11C-one (11C-
CGP12177),153 and (S)-4-(3-(2’-11C-isopropylamino)-
2-hydroxypropoxy)-2H-benzimidazol-2-one (11C-CGP
12388)154 have been reported for assessing postsynaptic
sympathetic neuronal functions through measurement of
myocardial b-adrenergic receptor (b-AR) density, which
directly regulatesLVsystolic function.155There are several
reports regarding tracers for imaging the parasympathetic
nervous system,156,157 but the clinical role of these has not
yet been established (Table 4).
Imaging of Inflammation and
Atherosclerosis
Nuclear medicine imaging can be used to view
several in vivo pathological processes in inflammation
and atherosclerosis. Several novel tracers may have uses
Figure 9. Representative case of 123I-MIBG scintigraphy and 11C-hydroxyephedrine PET A
male in his 40s suffered from dilated cardiomyopathy, with a left ventricular ejection fraction of
approximately 30%. An early anterior planar image at 15 min after injection (A) and a late
anterior planar image starting at 4 hours after injection (B) are acquired to calculate the heart-to-
mediastinum ratio (HMR) and the washout ratio. Calculated early HMR, delayed HMR, and
washout ratio were 1.7, 1.4, and 40.3%, respectively. Whole retention index from 11C-
hydroxyephedrine PET was calculated as 0.044. Distribution of sympathetic nerve system was
lower especially in the lateral wall.
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for tracking inflammation, hypoxia, or active calcifica-
tion (Table 5).
SPECT tracers for imaging of inflammation
and atherosclerosis. Gallium-67 (67Ga) scintigra-
phy has been used to detect inflammatory lesions
including infection and sarcoidosis.158,159 Several fac-
tors influence 67Ga accumulation in inflammatory
lesions. These factors include increased delivery and
accumulation of transferrin-bound 67Ga due to increased
blood flow and vascular membrane permeability. The
tendency of 67Ga to bind to lactoferrin and leukocytes
also leads to highly concentrated uptake of 67Ga.160
Imaging is performed at 48 to 72 hours after tracer
injection. In clinical settings, physicians ideally look to
have results immediately following a diagnostic test, and
therefore a late imaging protocol is one of the major
limitations of 67Ga. 67Ga scanning is useful to differen-
tiate acute myocarditis from acute myocardial
infarction.161 67Ga scintigraphy has been a major ana-
lytical tool in the diagnosis of cardiac sarcoidosis.162
There is no significant distribution in normal myocar-
dium.163 This is an advantage of 67Ga when applied to
cardiac sarcoidosis. However, generally speaking, 67Ga
has a limited role in the evaluation and management of
sarcoidosis.163
Inflammatory cells such as granulocytes, lympho-
cytes, and macrophages are migrated into inflammatory
lesions, resulting in the activation of a biological defense
mechanism. SPECT imaging with indium-111 (111In)-
radiolabeled autologous white blood cells (WBC) has
proven to be valuable in the detection of endocarditis.
111In-WBC is highly specific for infectious lesions
because granulocytes are recruited to the site of inflam-
matory foci but have limited sensitivity due to a weak
signal.164–166
Apoptosis imaging. Tissue apoptosis is consid-
ered to be one of the earlier stages of vascular plaque
rupture,167 and therefore detecting apoptotic lesions may
precipitate effective treatments to prevent cardiovascu-
lar events. Apoptotic cells externalize negatively
charged phosphatidylserine (PS).15 Human protein
annexin A5 binds to PS. 99mTc-labeled annexin A5 has
been shown to have higher uptake in the carotid arteries
of vulnerable stroke patients.168 99mTc-tagged annexin
A5 specifically accumulates in vascular atherosclerotic
lesions, which is a great advantage. In contrast, the
signal intensity of 99mTc-labeled annexin A5 is quite a
bit lower than that of 18F-FDG.169 99mTc-labeled
annexin A5 drew much interest a decade ago but has
not had wide clinical application, perhaps due to the
lower signal intensity and tracer availability.
PET tracers for imaging of inflammation
and atherosclerosis. Glucose is consumed in large
quantities in the inflammatory process, and therefore
Figure 10. Representative case of cardiac sarcoidosis Maximum intensity projection (MIP)
image of 18F-FDG PET (A), PET/CT coronal image (B), short-axis image of 18F-FDG PET (C),
late gadolinium enhancement (LGE)-MRI (D), and fused image of 18F-FDG PET and LGE-MRI
(E) at pre-therapy, MIP image of 18F-FDG PET (F) and PET/CT coronal image (G) at post-
therapy (steroid 30 mg/1 month) are displayed. 18F-FDG PET detected focal cardiac uptake and
multiple lymph node disease in the supraclavicular, mediastinum, hilum, abdominal, and pelvis
region at pre-therapy. 18F-FDG uptake is seen at the same site of LGE-MRI abnormal intensity.
At post-therapy, 18F-FDG uptakes were markedly lower. 18F-FDG is useful not only for
diagnosis but also to confirm the effectiveness of treatments.
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active inflammatory lesions show high 18F-FDG accu-
mulations. It is necessary to suppress physiological
myocardial glucose metabolism in order to accurately
evaluate myocardial inflammatory lesions using 18F-
FDG PET. Among effective approaches to reducing
physiological myocardial glucose metabolism, long-
period fasting is the most common. Long-period fasting
combined with a low-carbohydrate diet and/or high-fat
diet and unfractionated heparin intravenous injection are
also used. These approaches lead to myocardial free
fatty acid metabolism dominance.170 18F-FDG PET is
more useful than are perfusion SPECT and delayed
enhanced cardiac magnetic resonance (CMR) to not only
diagnose but also monitor treatment effects in inflam-
matory heart disease such as cardiac sarcoidosis
(Figure 10).171 Myocardial ischemia (reflecting a shift
to glucose metabolism), other cardiomyopathy (reflect-
ing microcirculatory ischemia and inflammation), and
cardiac tumors also show 18F-FDG accumulation.172–175
Incomplete suppression of physiological myocardial
18F-FDG uptake may cause false positives. Therefore,
new tracers have been developed to detect inflammatory
heart disease and atherosclerotic lesions. These radio-
pharmaceuticals target tissue apoptosis, tissue
calcification, activated macrophages, and tissue hypoxia.
68Ga complexed with [1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetraacetic acid]-1-Nal3-octreotide (68Ga-
DOTANOC),176 fluorine-18 fluorothymidine (18F-
FLT),177 68Ga complexed with [1,4,7,10-tetraazacy-
clododecane-1,4,7,10-tetraacetic acid]-Phe1-Tyr3-
octreotide (68Ga-DOTATOC),178 and fluorine-18 fluo-
romisonidazole (18F-FMISO)179 have been reported to
improve specificity with regard to diagnosis of cardiac
sarcoidosis.
68Ga-tagged tracers can be prepared using a gener-
ator system and have been applied for clinical oncology
imaging. Activated macrophages show upregulated G-
protein-coupled somatostatin receptor subtype-2 recep-
tors. In an observational study involving oncology
patients, uptake of 68Ga complexed with a somatostatin
analog, 1,4,7,10-tetraazacyclododecane-1,4,7,10-te-
traacetic acid-D-Phe1-Tyr3-octreotate (68Ga-
DOTATATE), in large arteries increased in relation to
age.180 A recent study prospectively revealed 68Ga-
DOTATATE uptakes in carotid and coronary arteries in
patients with unstable CVD.181 Unlike 18F-FDG, 68Ga-
DOTATATE does not have physiological myocardial
uptake and therefore could potentially play a clinical
role in detecting vulnerable plaque.
An alternative to 68Ga, Copper-64 (64Cu) com-
plexed with the somatostatin analog (64Cu-
DOTATATE) has been used. 64Cu has a shorter positron
range and longer half-life. Thus, 64Cu DOTATATE may
have improved spatial resolution over that of 68Ga-
DOTATATE. 64Cu DOTATATE also showed positive
uptake in carotid atherosclerotic lesions.182 64Cu-labeled
DOTATATE uptake was positively linked to the
expression of membrane receptor CD163, indicating
that 64Cu-labeled DOTATATE uptake was associated
with hemorrhagic macrophage migration.
Translocator protein. Translocator protein
18kDa (TSPO), a peripheral-type benzodiazepine recep-
tor, locates in peripheral tissue and the brain.183 TSPO is
a protein highly expressed in activated cells of the
mononuclear phagocyte lineage.184 Carbon-11 labeled
[1-(2-chlorophenyl)-N-methyl-N-1(1-methylpropyl)-3-
isoquinolinecarboxamide] (11C-PK11195) is a first
specific ligand for TPSO, and its uptake has been
revealed in symptomatic carotid atherosclerotic
lesions.185 However, 11C-PK11195 has some limitations
such as high non-specific binding and high lipophilicity.
To overcome these limitations, we developed an 18F-
labeled TPSO ligand, N-benzyl-N-methyl-2-[7,8-dihy-
dro-7-(2-[18F]fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-
yl] acetamide (18F-FEDAC). 18F-FEDAC showed high
in vitro binding affinity for TSPO with high selectiv-
ity.186 18F-FEDAC was initially developed as a tracer
for imaging brain inflammation, and subsequent study
revealed that this tracer could potentially be used for
imaging inflammation in peripheral organs.187 Indeed,
18F-FEDAC can be used to visualize lesions in rat
liver.14,188 In a rat lung injury model, 18F-FEDAC
uptake increased with the progression of lung inflam-
mation (Figure 11).189 The uptake of 18F-FEDAC in the
heart of a rat was approximately twice as high as that in
the lung.187 With 18F-FEDAC the uptake ratio for heart
to lung is higher than that with 13N-NH3. The same is
true for the heart-to-liver uptake ratio measured with
each of these tracers respectively. However, uptake
ratios are similar for heart to lung and heart to liver
measured using 18F-FEDAC and 18F-FDG (Figure 12).
In this regard, 18F-FEDAC may have potential for
detecting cardiac inflammatory lesions or vascular
inflammatory lesions.
Fluorine-18 anion (18F-), which is administered as
the sodium salt 18F-NaF, has been used as a bone-imaging
agent to detect metastatic bone lesions. Since 18F-
accumulates in calcification lesions, it has also been used
to evaluate the severity or disease activity of aortic
stenosis.190 During the progression of atherosclerosis,
calcification may appear in intermediate lesions. In
contrast, with inflammation, active calcification may
appear during the later stages of disease progression.
However, it is still important to detect actively progress-
ing calcification, because this may be one of the signs of
plaque rupture.191 Prospective studies with clinical out-
comes are ongoing to assess whether coronary 18F uptake
represents a future cardiovascular risk.
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SUMMARY AND CONCLUSION
Nuclear cardiology using targeted tracers via
SPECT and PET allows for diagnosis through non-
invasive imaging. Not only myocardial perfusion but
also cardiac metabolism, sympathetic nervous
system activity, and inflammatory disease are targeted
by nuclear cardiology using specific radiopharma-
ceuticals.
Figure 12. Histology showed leukocyte infiltration in the lung injury model. Scale bar: 20 lm.
18F-FEDAC showed higher uptake ratios of heart/lung and heart/liver compared to those with
13N-NH3 and similar to that with
18F-FDG. 18F-FDG, 18F-fluorodeoxyglucose; 18F-FEDAC, N-
benzyl-N-methyl-2-[7,8-dihydro-7-(2-[18F]-fluoroethyl)-8-oxo-2-phenyl-9H-purin-9-yl]
acetamide.
Figure 11. 18F-FEDAC imaging a comparison between 18F-FEDAC imaging and double
staining of translocator protein (TSPO) for neutrophils. Arrows indicate examples of cells
doubly positive for TSPO (green) and chloroacetate esterase (red spots) staining. Control group
showed no positive 18F-FEDAC uptake in either lung (A). No neutrophils were seen in the
control. Lung injury model using lipopolysaccharide showed positive 18F-FEDAC uptake in
both lungs (B).
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